← feed

Is NCT05305222 results overdue?

Yes — results are overdue. Primary completion was 2018-06-15; the FDAAA-801 reporting deadline (2019-06-15) passed 2609 days ago and no results are posted on ClinicalTrials.gov.

A Study in Healthy Japanese and Caucasian Subjects to Assess the Pharmacokinetics, Safety and Tolerability of Risankizumab

NCT IDNCT05305222 ↗
SponsorAbbVie (INDUSTRY)
Public issuerAbbVie Inc. — ABBV (CIK 0001551152) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2018-06-15 (ACTUAL)
Reporting deadline2019-06-15 (completion + 365d)
Days overdue2609
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 5f88d644198390c2… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT05305222. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →